{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "JPY", "exchange": "JPX", "shortName": "SYMBIO PHARMACEUTICALS LTD", "longName": "SymBio Pharmaceuticals Limited", "messageBoardId": "finmb_28896184", "exchangeTimezoneName": "Asia/Tokyo", "exchangeTimezoneShortName": "JST", "gmtOffSetMilliseconds": 32400000, "market": "jp_market", "esgPopulated": false, "regularMarketChangePercent": -1.0840108, "regularMarketPrice": 365.0, "marketState": "CLOSED", "firstTradeDateMilliseconds": 1319068800000, "priceHint": 2, "epsTrailingTwelveMonths": 25.44, "epsForward": 39.1, "sharesOutstanding": 39608400, "bookValue": 215.451, "fiftyDayAverage": 431.62, "fiftyDayAverageChange": -66.619995, "fiftyDayAverageChangePercent": -0.15434872, "twoHundredDayAverage": 616.985, "twoHundredDayAverageChange": -251.98499, "twoHundredDayAverageChangePercent": -0.40841347, "marketCap": 14457066496, "forwardPE": 9.335039, "priceToBook": 1.6941206, "sourceInterval": 15, "exchangeDataDelayedBy": 20, "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -4.0, "regularMarketTime": 1683872102, "regularMarketDayHigh": 375.0, "regularMarketDayRange": "365.0 - 375.0", "regularMarketDayLow": 365.0, "regularMarketVolume": 306900, "regularMarketPreviousClose": 369.0, "bid": 365.0, "ask": 366.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "Tokyo", "financialCurrency": "JPY", "regularMarketOpen": 371.0, "averageDailyVolume3Month": 518284, "averageDailyVolume10Day": 599350, "fiftyTwoWeekLowChange": 0.0, "fiftyTwoWeekLowChangePercent": 0.0, "fiftyTwoWeekRange": "365.0 - 930.0", "fiftyTwoWeekHighChange": -565.0, "fiftyTwoWeekHighChangePercent": -0.6075269, "fiftyTwoWeekLow": 365.0, "fiftyTwoWeekHigh": 930.0, "earningsTimestamp": 1682577000, "earningsTimestampStart": 1690957800, "earningsTimestampEnd": 1691389800, "trailingAnnualDividendRate": 0.0, "trailingPE": 14.347484, "trailingAnnualDividendYield": 0.0, "symbol": "4582.T"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Toranomon 30 Mori Building", "address2": "3-2-2 Toranomon Minato-ku", "city": "Tokyo", "zip": "105-0001", "country": "Japan", "phone": "81 3 5472 1125", "fax": "81 3 5472 3054", "website": "https://www.symbiopharma.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "industryDisp": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs and other related activities in the areas of oncology and hematology in Japan and internationally. It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and has completed the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma. The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid administrator. In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat lower-risk myelodysplastic syndromes (LR-MDS). Further, it develops SyB V-1901, an antiviral drug. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.", "fullTimeEmployees": 122, "companyOfficers": [{"maxAge": 1, "name": "Mr. Fuminori  Yoshida", "age": 73, "title": "CEO, Pres, Corp. Officer & Representative Director", "yearBorn": 1949, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Takaaki  Fukushima", "title": "Exec. Corp. Officer & CFO", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Masamichi  Mizutake", "title": "Director of Fin. and Accounting", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kiwami  Kurisawa", "title": "Director of Gen. Affairs and Legal Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Tatsuya  Yoneyama", "title": "Sr. Director of Bus. Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Shinji  Kunii", "title": "Director of Sales", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Koji  Fukushima", "title": "Corp. Officer & Chief Medical Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Yoshiharu  Torikai", "title": "Corp. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Masahiko  Okuno", "title": "Corp. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Hiroyuki  Horita", "title": "Corp. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "maxAge": 86400}}], "error": null}}